Biomarkers for the Prevention of Heart Failure: Are We There Yet?

Affiliations

¹ Section of Cardiology and Duke Clinical Research Institute (DCRI), Duke University School of Medicine, Durham, North Carolina. Electronic address: Michael.felker@duke.edu.
² Section of Cardiovascular Medicine and Center for Outcomes Research and Evaluation (CORE) at Yale University School of Medicine, New Haven, Connecticut.

Free article

Editorial

G Michael Felker et al. J Am Coll Cardiol. 2018.

Free article

. 2018 Dec 25;72(25):3255-3258.

doi: 10.1016/j.jacc.2018.09.077.

¹ Section of Cardiology and Duke Clinical Research Institute (DCRI), Duke University School of Medicine, Durham, North Carolina. Electronic address: Michael.felker@duke.edu.
² Section of Cardiovascular Medicine and Center for Outcomes Research and Evaluation (CORE) at Yale University School of Medicine, New Haven, Connecticut.

No abstract available

Keywords: biomarker; cardiovascular disease; change in galectin-3; galectin-3; heart failure; mortality.

Comment on

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.
Ghorbani A, Bhambhani V, Christenson RH, Meijers WC, de Boer RA, Levy D, Larson MG, Ho JE. Ghorbani A, et al. J Am Coll Cardiol. 2018 Dec 25;72(25):3246-3254. doi: 10.1016/j.jacc.2018.09.076. J Am Coll Cardiol. 2018. PMID: 30573026 Free PMC article.